ClinicalTrials.govpublic full text
A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care
multiple myeloma, belantamab, monoclonal antibody, b cell maturation antigen (bcma), subcutaneous belantamab (bcmab), intravenous, subcutaneous, standard of care, first line, second line, maintenance, autologous stem cell transplant (asct) maintenance treatment
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 884059
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.